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A B S T R A C T
Chronic obstructive pulmonary disease (COPD) is a multisystemic disease, one of the leading causes of mortality and
morbidity. The aim of this research is to assess the level of markers of endothelial dysfunction, vWf and the exhaled nitric
oxide (NO) depending on the severity of COPD. The study included 100 subjects: 60 patients with COPD without adjoin-
ing cardiovascular comorbidity, and 40 patients as the controls. The subjects underwent a fractional exhaled nitric oxide
test (FeNO), spirometric testing, and diffusing capacity of the lung for carbon monoxide test (DLCO), samples were taken
of their vein blood to analyze the level of vWf (using the vWf:RCO method), C-reactive protein (CRP), fibrinogen, choles-
terol, triglycerides as well as the acid base status. COPD patients then filled COPD assessment test (CAT test) and the
modified dyspnea scale (mMRC). The results showed that in patient group that higher levels of vWf are associated with
lower values of exhaled NO, which means that higher levels of vWf are associated with lower values of exhaled NO. By
comparing the ill subjects from four groups (A, B, C and D), a difference was established between the level of vWf [F (3.56
=0.24; p=0.869], while, although statistically not significant, the highest level of exhaled NO was found in group A and
the lowest in group D. The rise in the value of vWf is followed by the rise of fibrinogen values, which is another marker of
endothelial dysfunction. The results of this research have shown that a systemic inflammation and hypoxia in the early
stages of COPD, when no significant changes in the absolute values of FEV1 are present, stipulate the existence of endo-
thelial dysfunction together with the clinically relevant differences in the levels of vWf and exhaled NO.
Key words: COPD, endothelial dysfunction, nitric oxide, von Willenbrand factor, fibrinogen
Introduction
Chronic obstructive pulmonary disease (COPD) is a
complex multisystem disease and a leading cause of mor-
tality and morbidity. Systemic inflammation, which is a
consequence of smoking, leads to endothelial damage
and a subsequent reduction in vasodilator capacity (which
results in endothelial dysfunction), and initiates the
atherosclerotic process. COPD represents an independ-
ent risk factor for cardiovascular disease.1–3 The main
mechanisms in the development of endothelial dysfunc-
tion in patients with COPD are systemic inflammation,
hypoxia, oxidative stress, and sympathetic activation4.
Endothelial dysfunction is a syndrome with multisys-
temic effects and is marked by inappropriate endothelial
activation or loss of vasodilator, antithrombotic, and
anti-inflammatory capabilities. Dysfunctional endothe-
lium is also characterized by the increased expression of
adhesion molecules, chemokines, and other cytokines,
which play an important role in the initial stage of the
atherosclerotic process.
1153
Received for publication May 1, 2012
Methods that are now used to assess the endothelial
dysfunction include invasive methods that measure coro-
nary diameter and flow and noninvasive methods such as
the high-resolution ultrasound test flow-mediated dila-
tion of peripheral artery disease (which is considered the
»gold standard« in the diagnosis of endothelial dysfunc-
tion)5. Many studies have confirmed that among the
noninvasive methods of assessing endothelial dysfunc-
tion is detecting the presence of von Willebrand factor
(vWf)6. vWf is a multimeric glycoprotein synthesized pri-
marily in endothelial cells. The level of vWF, reflects gen-
eral endothelial functional disorder as well as the level of
activity of the atherosclerotic process5. The level of vWf
has been assessed in a series of clinical conditions. The
main advantage of vWF is its availability of detection.
Previous studies confirm that the level of vWF is posi-
tively correlated with the level of oxidative stress, which
plays a role in the development of the atherosclerotic
process7,8. Endothelial dysfunction is associated with the
reduced bioavailability of nitric oxide (NO) because of its
reduced production by endothelial cells and/or because of
increased inactivation of NO synthase by reactive oxygen
species, which occurs in numerous inflammatory condi-
tions5,9,10.
Previous studies evaluating the level of NO in the
breath of patients with COPD have shown that the level
of NO is correlated with the general condition of the pa-
tient and the level of the post-bronchodilator forced expi-
ratory volume in 1 second (FEV1)11–14. The use of inhaled
corticosteroids or bronchodilators does not affect the NO
level15–17. Research results have confirmed the interde-
pendence of NO and vWf levels in the development of the
atherosclerotic process and confirmed that the reduced
production of NO results in increased levels of vWF,
which partially blocks the action of NO synthase14,18. Dif-
ferent research methods have confirmed endothelial dys-
function in patients with COPD19–21 and that the plasma
concentrations of markers of endothelial dysfunction in-
crease significantly with each exacerbation of COPD, in-
dependent of concomitant cardiovascular comorbidi-
ty22–25.This study aims to determine whether the level of
vWf increases as the level of exhaled NO decreases in pa-
tients with increasing severity of COPD26, and to deter-
mine whether there are differences between patients
with and without elevated cholesterol and triglyceride
levels. The assessment of endothelial dysfunction in pa-
tients with COPD is extremely important clinically and
for determining the appropriate treatment for the mul-
tisystem consequences of COPD.
Materials and Methods
The study included 100 subjects: 60 patients with
COPD, who were treated at the Department of Pulmo-
nary Diseases at the Department of Internal Medicine at
the University Hospital Osijek (Osijek, Croatia) and 40
controls (20 healthy smokers with normal lung function
and 20 nonsmokers) in the period of May 2012. to June
2013. The patients and controls were over 18 years. Pa-
tients who had acute exacerbation of COPD, malignant
diseases, radiological signs of pulmonary hypertension,
asthma, chronic renal failure, or patients who were regu-
larly taking angiotensin-converting enzyme inhibitor
blockers, angiotensin receptor blocker statins, oral cor-
ticosteroids, or hypoglycemic agents were excluded from
the study. The participants were previously familiar with
the investigation and provided signed informed consent.
The study was approved by the Ethics Committee of the
University Hospital Osijek (Osijek, Croatia) and con-
ducted according to the principles of the Helsinki Decla-
ration. A case history was obtained from all study partici-
pants in regard to hypertension, diabetes, duration and
amount of smoking, coronary heart disease, stroke, pe-
ripheral artery disease. They also underwent a physical
examination. Their body height and weight were mea-
sured. Based on these data, each study participant’s body
mass index (BMI) was calculated.
Respondents underwent standardized noninvasive
measurement of fractional exhaled NO (ppb), spirome-
tric testing, and measurement of the diffusing capacity of
the lung for carbon monoxide (DLCO). Venous blood
samples were collected from each subject for the nonin-
vasive analysis of the levels of vWF, C-reactive protein
(CRP, reference range <0.5 mg/L), fibrinogen (reference
range 1.8–3.5 g/L), cholesterol (reference range <5.00
mmol/L), and triglycerides (reference range <1.70
mmol/L). A sample of arterial blood was obtained for the
analysis of each subject’s acid-base status. Laboratory
determination of the vWf level (reference range 0.50–
1.50 L) was obtained by the von Willebrand-ristocetin co-
factor test (vWF:RCO), which measures platelet aggluti-
nation in plasma in the presence of ristocetin. The ris-
tocetin-induced agglutination rate is correlated with the
concentration and the functional activity of plasma vWF.
Ristocetin binds to vWF on Glu1239-Pro-Gly Gly1242.
Participants who had COPD completed the following
questionnaires: COPD assessment test (CAT) and the
modified dyspnea scale (mMRC). These participants
were divided into 4 groups based on the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guideli-
nes26 or based on the results of spirometry, the risk of ex-
acerbations, and the presence of symptoms (as assessed
by the questionnaires) (Table 1).
Statistical analysis
The collected data were analyzed by the statistical
program SPSS for Windows, version 19 (IBM, New York,
United States) before the processing of data. The Sha-
piro-Wilk normality test was used to determine the dis-
tribution of the numerical variables. We used t-tests to
compare 2 independent groups and analysis of variance
(ANOVA) and analysis of covariance (ANCOVA) to com-
pare 2 or more independent groups. ANCOVA is different
from the well-known and more frequently used ANOVA,
in that it allows for controlling the effects of certain vari-
ables. The sample size required for this study was deter-
mined by using the calculated required sample size
(G*Power 3 Germany).
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Results
Data were collected for one hundred subjects aged 34
to 79 (X=54.64; SD=11.70). The participants were di-
vided into two groups: 1) the patient group (n=60) and 2)
the control group (N=40). The control group was divided
into two subgroups, namely A) smokers (n=20) and B)
nonsmokers (N=20). The age range in the patient group
from 42 to 79 years and the average age is M=60.67
years (SD=9.28). The age range of the control group of
smokers goes from 35 to 65 years with an average age be-
ing X = 44.79 years (SD=9.00). The average age of the
control group of nonsmokers is X=45.47 (SD=7.91 years;
the age range is 34–60 years). According to the GOLD
guidelines (the 2011 classification), with reference to the
spirometry findings, the risk of exacerbations and the
presence of symptoms which are assessed by the ade-
quate questionnaire, the patients were divided into 4
groups. While doing so, twenty of them were categorized
into group A, 26 into group B and 7 patients into groups
C and D.
By comparing the participants from the four groups
(A, B, C and D) the difference in the level of vWf [F
(3.56)=0.24; p=0.869] and the level of exhaled NO [F
(3.56)=1.45; p=0.239] was determined. The highest level
of exhaled NO was found among the participants from
group A, and the lowest among the patients from group
D (Table 2).
A comparison of the four patients groups (i.e., A, B, C
and D) showed that there was no significant difference in
the level of vWF [F (3.56)=0.24; p=.869] or the level of
exhaled NO [F (3.56)=1.45; p=0.239]. The difference
was not statistically significant (Table 2); however, the
participants in group A had the highest level of exhaled
NO and the participants in group D had the lowest level
of exhaled NO. Within the group of the patients and the
control group of nonsmokers the higher readings of vWf
are associated with the lower reading of exhaled NO
(Figure 1). Furthermore, it was established in all three
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TABLE 1







A Low risk Less symptoms GOLD 1-2 <1 0–1 <10
B Low risk More symptoms GOLD 1-2 <1 ³2 ³10
C High risk Less symptoms GOLD 3-4 ³2 0–1 <10
D High risk More symptoms GOLD 3-4 ³2 ³2 ³10
mMRC – Modiefied British Research Coucinl breathlessness scale, CAT – COPD Assessment test, GOLD – Global initiative for chronic
Obstructive Lung Disease
TABLE 2
DESCRIPTIVE STATISTICS FOR VWF AND EXHALED NO IN PARTICIPANTS WITH VARYING SEVERITY OF COPD
Patient N X SD Minimum Maximum
vWf(L)
A (low risk, less symptoms) 20 1.62 0.57 0.52 3.18
B (low risk, more symptoms) 26 1.51 0.59 0.74 3.60
C (high risk, less symptoms) 7 1.54 0.65 0.58 2.30
D (high risk, more symptoms) 7 1.43 0.48 0.58 2.07
Exhaled NO
(ppb)
A (low risk, less symptoms) 20 16.35 8.26 4 40
B (low risk, more symptoms) 26 15.19 8.81 2 38
C (high risk, less symptoms) 7 11.43 4.42 6 17
D (high risk, more symptoms) 7 10.43 2.14 8 14
N – number of patient, vWf – von Willenbrand factor, NO – nitric oxide
Fig. 1. Relationship between levels of vWf and exhaled NO in the
group of patients.
participant groups that with the increase of the vWf
value, the value of fibrinogen level also increases (Table
3).
As shown in Tables 3–3b, from all the other tested
markers in all three groups it was, as expected, estab-
lished that lower values of pO2 are followed by higher
values of vWf. In the patient group was found that the in-
crease of vWf values is followed by decreased BMI values
(Table 3). In the same group it was established that the
increase of pack/years (the number of cigarettes smoked
in a day) x (years of smoking)/20, is followed by a lower
vWf value, but if only current smokers are taken from
the patient group, higher vWf values are connected to
more smoked cigarettes and more years of smoking (r=
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TABLE 3
INTERCORRELATIONS AMONG THE TESTED MARKERS IN THE THREE GROUP OF PATIENT
Patient
(N=60)
2 3 4 5 6 7 8 9 10 11 12 13 14
1. vWf –0.17 0.30* 0.30* –0.05 0.16 0.10 0.04 0.33* –0.07 0.09 0.22 –0.29* –0.29*
2. Exhaled NO — –0.12 –0.17 –0.03 –0.10 0.17 0.18 0.08 –0.11 –0.06 –0.04 0.02 0.04
3. Fibronogen — 0.53† –0.03 –0.04 –0.09 –0.07 –0.13 –0.14 –0.08 0.05 0.01 –0.17
4. CRP — –0.20 0.13 –0.17 –0.01 0.04 –0.11 –0.01 0.15 –0.04 –0.07
5. Cholesterol — 0.30* 0.28* 0.18 0.19 0.11 0.15 0.08 0.32* 0.02
6.Tryglicerides — 0.17 0.25 0.27* –0.10 0.04 –0.05 0.26* –0.11
7. FEV1 — 0.68† 0.47† –0.08 –0.18 –0.11 –0.03 –0.07
8. FEV1/FVC — 0.41† –0.06 –0.06 –0.01 0.14 –0.14
9. DLCO — –0.04 –0.06 –0.09 0.26* –0.27*
10. pO2 — 0.03 –0.06 –0.17 –0.14
11. pCO2 — 0.82† –0.04 –0.02
12. HCO3– — –0.10 –0.11
13.BMI — 0.10
14. pack/years —
*p<0.05, †p<0.01, ‡p<0.001, FEV1 – post-bronchodilator forced expiratory volume in 1 second, FEV1/FVC – post-bronchodilator
forced expiratory volume in 1 second/forced vital capacity, DLCO – diffusing capacity of lung for carbon monoxide, pO2 – partial pres-
sure of oxygen, pCO2 – partial pressure of carbon dioxide, HCO3– – bicarbonate, BMI – body mass index
TABLE 3a
INTERCORRELATIONS AMONG THE TESTED MARKERS IN THE GROUP OF CONTROL SMOKERS
Control smokers
(N=20)
2 3 4 5 6 7 8 9 10 11 12 13 14
1. vWf 0.09 0.19 0.19 0.08 0.17 –0.18 –0.15 –0.46* –0.11 –0.44 –0.34 –0.25 0.13
2. Exhaled NO — 0.61† 0.72† 0.11 –0.15 –0.04 –0.06 0.11 –0.88† –0.05 –0.20 0.20 0.56*
3. Fibronogen — 0.49* –0.31 –0.49* 0.14 –0.11 –0.05 –0.64† 0.15 –0.12 0.16 0.17
4. CRP — 0.09 –0.10 0.00 –0.01 0.18 –0.82† 0.23 –0.04 0.29 0.20
5. Cholesterol — 0.81† 0.18 0.36 0.51* –0.11 –0.16 –0.08 0.43 0.27
6.Tryglicerides — 0.03 0.30 0.43 0.19 –0.30 –0.18 0.44 0.05
7. FEV1 — 0.31 0.57* 0.08 0.08 0.01 0.26 –0.34
8. FEV1/FVC — 0.47* 0.15 –0.24 –0.18 0.36 0.01
9. DLCO — –0.01 0.09 0.03 0.54* –0.14
10. pO2 — –0.01 0.21 –0.16 –0.52*
11. pCO2 — 0.80† –0.10 –0.34
12. HCO3– — –0.26 –0.31
13. BMI — 0.30
14. pack/years —
*p<0.05, †p<0.01, ‡p<0.001, FEV1 – post-bronchodilator forced expiratory volume in 1 second, FEV1/FVC – post-bronchodilator
forced expiratory volume in 1 second/forced vital capacity, DLCO – diffusing capacity of lung for carbon monoxide, pO2 – partial pres-
sure of oxygen, pCO2 – partial pressure of carbon dioxide, HCO3– – bicarbonate, BMI – body mass index
0.06; p=0.781), just as with the control group of smokers
(Table 3a). By using T-test for independent samples it
was found that the average value of pack/years was sig-
nificantly larger among the patients (X=37.80; SD=
33.90) than among the control group of smokers (X=
16.10; SD=10.36). As can be seen in Table 4, after the
age control, as expected, a significant difference between
the three groups was found regarding the level of exhaled
NO, spirometry findings, diffusion capacity and the par-
tial oxygen pressure. For each significant difference, the
magnitude of the effect of the difference was calculated.
As can be seen in Table 4, the magnitude of the differ-
ence for exhaled NO and pO2 is moderate (according to
Cohen’s border values), and for DLCO, FEV1 and FEV1/
FVC it is great. Practically, it means that the differences
between the groups considering the values of individual
markers are not just statistically, but also clinically sig-
nificant, in other words, relevant.
By using the statistical analysis it was found that
within the group of ill participants, 42 of them (70%) had
elevated cholesterol, and 18 of them (30%) had elevated
triglycerides. In the control group of smokers a similar
percentage (63.2%) had elevated cholesterol, and one
third (31.6%) also had elevated triglycerides, whereas in
the nonsmokers’ group as much as 71.85% of them had
elevated cholesterol, and around one third (31.2%) had
elevated triglycerides. By using T-test for independent
samples, no differences were found in vWF [t (96)=0.20;
p=0.841] and fibrinogen values [t (96)=1.31; p=0.193]
for those participants with higher levels of cholesterol
and triglycerides compared to the other participants.
The comparison of the patients undergoing different
types of therapy regarding the usage of inhalational
corticosteroids established that, from the entire number
of patients, 47 of them were receiving treatment with
inhalational corticosteroids. By using T-test for inde-
pendent samples, a difference was established between
the two participant groups regarding the values of ex-
haled NO, t (57)=2.23; p=0.032, in which process among
the ill ones who had inhalational corticosteroid in their
therapy, a lower value of exhaled NO was measured
(X=13.45; SD=6.84) than within the participants who
weren’t receiving the aforementioned therapy (X=
18.92; SD=10.43). By using the same test no difference
was found between the two participant groups regarding
the vWf values t(57)=1.29; p=0.203, although higher
vWf values were noticed in the group which received a
therapy without the inhalational corticosteroids than
within the group which received therapy with inhala-
tional corticosteroid (X=1.50; SD=0.62). Finally, by pro-
cessing it was established that a longer period of treat-
ment (expressed in months) was followed by higher vWf
values (r=17; p=0.198).
Discussion
This research, in accordance with the previous re-
searches, has confirmed the existence of endothelial dys-
function in patients with COPD using as markers the
level of serum vWf and the exhaled NO,23–26 with the em-
phasis that, unlike with the majority of previous re-
searches, the ill ones didn’t have associated cardiovascu-
lar comorbidity. By excluding one of the most important
factors that affects endothelial dysfunction, and includ-
ing only the ill ones in a stable stage of the disease, the
research had the goal to, as precisely as possible, and as
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TABLE 3b
INTERCORRELATIONS AMONG THE TESTED MARKERS IN THE GROUP OF CONTROL NON- SMOKERS
Control non-
smokers (N=20)
2 3 4 5 6 7 8 9 10 11 12 13 14
1. vWf –0.25 0.56* –0.01 0.26 0.15 –0.18 0.24 0.24 –0.23 0.04 0.06 0.12 –0.08
2. Exhaled NO — –0.08 0.08 –0.24 0.12 0.15 –0.19 –0.18 –0.09 0.20 0.11 0.05 –0.22
3. Fibronogen — 0.52* –0.08 0.42 0.24 –0.21 –0.05 –0.49* –0.03 –0.33 0.26 0.03
4. CRP — 0.06 0.75† –0.06 –0.13 0.11 –0.36 –0.40 –0.62† 0.42 –0.21
5. Cholesterol — 0.15 –0.30 0.26 0.13 0.29 –0.37 –0.32 0.44 0.17
6.Tryglicerides — –0.27 –0.07 0.17 –0.37 –0.38 –0.47* 0.24 –0.12
7. FEV1 — –0.03 0.16 0.23 –0.13 –0.32 –0.03 –0.06
8. FEV1/FVC — 0.57* 0.43 –0.45 –0.18 0.04 –0.21
9. DLCO — –0.44 –0.27 –0.47* –0.10 –0.44
10. pO2 — –0.44 –0.27 –0.47* –0.10
11. pCO2 — 0.85† 0.01 0.05
12. HCO3– — –0.15 0.09
13. BMI — –0.05
14. pack/years —
*p<0.05, †p<0.01,‡ p<0.001, FEV1 – post-bronchodilator forced expiratory volume in 1 second, FEV1/FVC – post-bronchodilator
forced expiratory volume in 1 second/forced vital capacity, DLCO – diffusing capacity of lung for carbon monoxide, pO2 – partial pres-
sure of oxygen, pCO2 – partial pressure of carbon dioxide, HCO3– – bicarbonate, BMI – body mass index
realistically, assess the systemic effects of COPD. Due to
the high percentage of associated cardiovascular comor-
bidity (14–62% of COPD patients) which increases with
the progress of COPD, the research is limited to an iso-
lated population of patients with COPD which explains
the sample size in this study27. In this research fibri-
nogen was used as a control marker of endothelial dys-
function, whose values correlate positively with vWf, and
the level of exhaled NO is decreased by the growth of the
aforementioned two markers. These results are consis-
tent with previous findings showing that endothelial dys-
function is associated with the reduced activity of NO
synthase, which is simultaneously blocked by the in-
crease in vWF levels22. Taking into account the severity
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TABLE 4
COMPARISON OF THE THREE GROUPS OF PARTICIPANTS WITH REGARD TO SEROLOGICAL MARKERS








2.58 0.05Control smokers 1.48 0.83
Control non-smokers 1.08 0.45
Exhaled NO
Patient 14.58 7.86
4.19* 0.08 P<CSControl smokers 19.42 13.85
Control non-smokers 13.00 6.11
Fibronogen
Patient 4.19 1.13
0.38 0.01Control smokers 3.35 1.22
Control non-smokers 3.19 0.96
CRP
Patient 5.64 6.54
0.33 0.01Control smokers 2.48 3.22
Control non-smokers 2.82 2.69
Cholesterol
Patient 5.50 1.01
1.01 0.02Control smokers 5.80 1.73
Control non-smokers 5.72 1.03
Tryglicerides
Patient 1.41 0.71
0.08 0.01Control smokers 1.70 1.06






Control smokers 105.51 13.75
Control non-smokers 115.62 10.91
FEV1/FVC
Patient 57.65 9.01 37.97† 0.45
P<CS,
P<CNS
Control smokers 80.90 7.45






Control smokers 78.71 12.13
Control non-smokers 93.70 12.00
pO2
Patient 9.69 1.37
3.69* 0.07 CS<CNSControl smokers 10.68 3.87
Control non-smokers 12.23 1.33
pCO2
Patient 5.26 0.54
0.12 0.01Control smokers 5.17 0.41
Control non-smokers 5.25 0.62
HCO3–
Patient 25.56 2.12
0.15 0.01Control smokers 25.15 1.37
Control non-smokers 25.48 2.18
çp
2 – mesure of efect size, vWf – von Willenbrand factor, *p<0.05, P – patient, CS – control smokers, FEV1 – post-bronchodilator forced
expiratory volume in 1 second, †p<0.001, CNS – control non-smokers, FEV1/FVC – post-bronchodilator forced expiratory volume in 1
second/forced vital capacity, DLCO – diffusing capacity of lung for carbon monoxide, pO2 – partial pressure of oxygen, pCO2 – partial
pressure of carbon dioxide, HCO3– – bicarbonate
of COPD (GOLD’s guidelines, the 2013 classification), it
is necessary to emphasize that most patients, according
to the seriousness of the disease, belong to groups A and
B because with the advancement of the disease, the pres-
ence of comorbidities which independently of COPD af-
fect the endothelial dysfunction is more significant, whe-
reas the level of exhaled NO was, in accordance with the
assumptions, the lowest in group D; in other words, it de-
creased with the increase of the severity of COPD.
As expected, with a longer period of treatment, there
is a progression in endothelial dysfunction, which is con-
firmed by the data about positive correlation between
the length of the treatment and the vWf level.
When discussing the current smoking status, the con-
trol group of smokers, as well as the current smokers in
the ill-group, had higher values of exhaled NO in com-
parison to the rest of the patients because active smoking
transitorily increases the oxidative stress in the airways,
which results in an increase in exhaled NO28,29. The re-
sults obtained in this research have shown that the appli-
cation of inhalation corticosteroids with the patients
with COPD leads to a decrease in NO level30, which can
be explained by the fact that their application increases
as the severity of the disease enhances (according to
GOLD’s guidelines), thus resulting in, as we mentioned
earlier, decreasing the level of exhaled NO.
Taking into account BMI, the vWF value was elevated
in patients with lower BMI values which stems from the
fact that the loss of body weight is the result of increased
levels of inflammatory markers and hormonal changes,
which presents a negative survival predictor. In doing so
it confirms the fact that the range of the entire inflam-
matory process itself is responsible for the development
of endothelial dysfunction.
The results of this research have shown that the sys-
temic inflammation, hypoxia in the early stages of COPD
when there are no significant changes in the absolute
values and FEV1, are responsible for clinically relevant,
although not statistical, considerable increase in endo-
thelial dysfunction markers. These results can be ex-
plained by the small sample size, but it has to be empha-
sized that the sample size is the result of the fact that
only about 10% of those with COPD are without adjoin-
ing comorbidity and are not taking medications which in-
fluence the interpretation of the endothelial dysfunc-
tion’s markers. The advantage of these two markers of
endothelial dysfunction compared with the others is
their clinical availability. Future researches should de-
termine how to apply aforementioned markers of endo-
thelial dysfunction in everyday clinical practice, in the
treatment of COPD and in monitoring the systemic con-
sequences of COPD.
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PROCJENA ENDOTELNE DISFUNKCIJE NA TEMELJU VON WILLENBRANDOVA FAKTORA
I IZDISAJNOG DU[IKOVA OKSIDA KOD OBOLJELIH OD KRONI^NE OPSTRUKTIVNE
PLU]NE BOLESTI
S A @ E T A K
Kroni~na opstruktivna plu}na bolest (KOPB) je multisistemska bolest, jedan od vode}ih uzroka mortaliteta i morbi-
diteta. Cilj ovog istra`ivanja je procjenti razinu markera endotelne disfunkcije vWf I izdisajnog du{ikova oksida (NO)
ovisno o stupnju te`ine KOPB-a.U istra`ivanje je uklju~eno ukupno 100 ispitanika, 60 oboljelih od KOPB-a bez pri-
dru`enog kardiovaskularnog komorbiditeta, a 40 ispitanika su kontrolne skupine. Ispitanici su u~inili FeNO test, spiro-
metrijskog testiranja, mjerenje difuzijskog kapaciteta za CO, uzeti su im uzorci venske krvi za analizu razine vWf
(metodom vWF:RCO), C-reaktivni protein (CRP), fibrinogena, kolesterola, triglicerida, te analiza acido-baznog statusa.
Oboljeli od KOPB-a potom su ispunili odgovaraju}e upitnike COPD assessment test (CAT test) and the modified dys-
pnea scale (mMRC). Rezultati su pokazali da u skupini oboljelih odnos izme|u vWf i izdisajnog NO je negativan {to
zna~i da su vi{e vrijednosti vWf povezane s ni`im vrijednostima FeNO. Usporedbom oboljelih iz ~etiri skupine (A, B, C i
D) utvr|ena razlika u razini vWf [F (3,56)=0,24, p=0,869], dok iako ne statisti~ki zna~ajna, najvi{a razina izdisajnog
NO utvr|ena u skupini A, a najni`a u skupini D. Porast vrijednosti vWf pra}en je porastom vrijednosti fibrinogena, jo{
jednog markera endotelne disfunkcije. Rezultati ovog istra`ivanja su pokazali da sistemska upala i hipoksija ve} u
po~etnim stadijima KOPB-a kad nisu prisutne zna~ajne promjene u apsolutnim vrijednostima FEV1 uvjetuju posto-
janje endotelne disfunkcije uz klini~ki relavantne razlike u razini vWf i izdisajnog NO.
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